Sign in Subscribe

braf

A collection of 55 issues

Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer

Skip to content The CRC Digest ◆ TRIAL DATA Oral TKI anlotinib shows non-inferiority to bevacizumab plus chemotherapy in first-line RAS/BRAF wild-type metastatic colorectal cancer The phase 3 ANCHOR trial (NCT04854668) compared CapeOX chemotherapy combined with anlotinib versus CapeOX combined with bevacizumab in patients with RAS/BRAF wild-type mCRC, evaluating

CRC Research Update — August 31, 2026

Today's colorectal cancer research highlights

NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis

Skip to content The CRC Digest ◇ RESEARCH NF-κB/Lipocalin 2 pathway may reduce chemoresistance in BRAF-mutant colorectal cancer by promoting ferroptosis Preclinical research found that the NF-κB/LCN2 signaling pathway enhances cisplatin sensitivity in BRAF V600E-mutant CRC cells through iron-dependent cell death. (Cancers) This content is informational only and does

CRC Research Update — August 30, 2026

Today's colorectal cancer research highlights

Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC

Skip to content The CRC Digest ◆ TRIAL DATA Final Analysis of DEEPER Trial in RAS/BRAF Wild-Type Metastatic CRC The DEEPER trial presents final analysis of long-term survival outcomes comparing modified-FOLFOXIRI plus cetuximab versus bevacizumab in patients with RAS and BRAF wild-type metastatic colorectal cancer. (Journal of Clinical Oncology) This

Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC

Skip to content The CRC Digest ◆ TRIAL DATA Final Analysis of DEEPER Trial Shows No Survival Difference Between Cetuximab and Bevacizumab in RAS/BRAF Wild-Type mCRC The phase II DEEPER trial found no differences in progression-free survival or overall survival in the per-protocol set when comparing modified-FOLFOXIRI plus cetuximab versus

CRC Research Update — August 27, 2026

Today's colorectal cancer research highlights

CRC Research Update — August 25, 2026

Today's colorectal cancer research highlights

Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China

Skip to content The CRC Digest Cost-effectiveness of triplet therapy for BRAF V600E-mutated metastatic CRC in China (Frontiers in Pharmacology) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

CRC Research Update — August 23, 2026

Today's colorectal cancer research highlights